Intensity Therapeutics 2025 net loss $11.6M; cash $11.9M; TNBC trial pCR 71% vs 33%

INTENSITY THERAPEUTICS, INC.

Net loss narrowed to $11.6M from $16.3M in 2024; R&D spend fell to $6.8M from $10.5M.
Cash and equivalents $11.9M at Dec 31, 2025; raised >$20M in 2025; runway into Q2 2027.
INVINCIBLE-4 TNBC trial: 5/7 (71.4%) pCR with INT230-6+SOC vs 2/6 (33%) SOC alone; fewer grade 3+ AEs.
INVINCIBLE-3 sarcoma trial paused in March 2025; 21 patients enrolled; restart depends on funding.
IT-01 study published in eBioMedicine: 75% disease control rate, median OS 11.9 months in refractory tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTENSITY THERAPEUTICS, INC. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025.

View on SEC.gov

1350 earnings releases filed in the last 30 days. Browse all earnings releases →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.